FoRx Therapeutics AG’s €10 Million Seed-Financing Round

VISCHER advises FoRx Therapeutics AG on all Swiss legal issues related to the transaction.

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners) also joined the seed-financing.

The VISCHER team includes Christian Wyss (Partner, Life Sciences, in picture), Dania Salvisberg-Schneider (Associate, Corporate / M&A), Luzius Zumstein (Associate, Corporate / M&A), Fiona Gao (Associate, Life Sciences), Beatrice Leistner (Associate, Tax), and Gian Geel (Associate, Employment).

Involved fees earner: Fiona Gao – VISCHER AG; Gian Geel – VISCHER AG; Beatrice Leistner – VISCHER AG; Dania Salvisberg-Schneider – VISCHER AG; Christian Wyss – VISCHER AG; Luzius Zumstein – VISCHER AG;

Law Firms: VISCHER AG;

Clients: FoRx Therapeutics AG;